Exelixis, Inc. (NASDAQ:EXEL) was founded in 1994, formerly Exelixis Pharmaceuticals, Inc., changed to its current name in February 2000, headquartered in South San Francisco, California, USA, with 85 full-time employees. It is a company engaged in the research, development and commercialization of small molecule therapy for cancer in the United States.
Exelixis products include:
- COMETRIQ-a multi-receptor tyrosine kinase inhibitor, used in the treatment of metastatic medullary thyroid cancer; in addition, the product has also been used in clinical trials for the treatment of other cancers (up to 45 simultaneous clinical trials Many), mainly in metastatic renal cell carcinoma (MRCC) and advanced hepatocellular carcinoma (HCC)
- Cobimetinib, a MEK inhibitor, is currently in a key Phase III clinical trial, mainly for newly treated patients with advanced metastatic melanoma.
Exelixis, Inc. currently cooperates with several big names in the industry, such as: Genentech , GlaxoSmithKline , Bristol-Myers Squibb , Sanofi , Merck and Daiichi Sankyo, etc., and its anti-cancer product industry generally believes It is comparable to JUNO .